New therapeutic targets for the antiphospholipid syndrome

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 12, 2010, Pages 1291-1299

  Pericleous, Charis ^a,b   Ioannou, Yiannis ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

2 glycoprotein I; antiphospholipid antibodies; antiphospholipid syndrome; targets

Indexed keywords

ANTICOAGULANT AGENT; ATORVASTATIN; BLOOD CLOTTING FACTOR 10A; CELL PROTEIN; DABIGATRAN; DILAZEP; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PRAVASTATIN; PROTHROMBIN; RITUXIMAB; RIVAROXABAN; THROMBOPLASTIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; CELL ACTIVATION; CELL SURFACE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; FIBRIN FORMATION; HUMAN; NONHUMAN; PATIENT SAFETY; REVIEW; THROMBOSIS;

ABORTION, HABITUAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; B-LYMPHOCYTES; BLOOD PLATELETS; ENDOTHELIAL CELLS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MOLECULAR TARGETED THERAPY; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS;

EID: 78249245750     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.524207     Document Type: Review

References (74)

1. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-51
2. Rai RS. Antiphospholipid syndrome and recurrent miscarriage. J Postgrad Med 2002;48:3-4
3. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1, 000 patients. Arthritis Rheum 2002;46:1019-27 (Pubitemid 34303815)
4. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530-4
5. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306
6. Turiel M, Sarzi-Puttini P, Peretti R, et al. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. Stroke 2005;36:1490-4
7. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010;8:237-42
8. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006;295:1050-7
9. Laux V, Perzborn E, Heitmeier S, et al. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost 2009;102:892-9
10. Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus 2010;19:486-91
11. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
12. Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008;112:2242-7
13. Buller HR. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism, the Einstein-Extension Study. Late breaking abstracts LBA-2, 51st ASH Annual Meeting and Exposition 2009. Available from: http://ash.confex.com/ash/2009/webprogram/ Paper25669.html [Last accessed 16 September 2010]
14. Meroni PL, Raschi E, Camera M, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000;15:237-40
15. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998;79:276-81
16. Cuadrado MJ, Buendia P, Velasco F, et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006;4:2461-9
17. Forastiero RR, Martinuzzo ME, de Larranaga GF. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus 2005;14:129-36
18. Forastiero RR, Martinuzzo ME, Broze GJ. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J Thromb Haemost 2003;1:718-24
19. Redecha P, Tilley R, Tencati M, et al. Tissue factor: a link betwen C5a and neutrophil activation in antiphospholipid antibody-induced fetal loss. Blood 2007;110:2423-31
20. Zhou H, Wolberg AS, Roubey RA. Characterisation of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004;104:2353-8 (Pubitemid 39331833)
21. Pierangeli SS, Erkan D. Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus 2010;19:475-85
22. Napoleone E, Di Santo A, Camera M, et al. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 2000;86:139-43
23. Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009;68:1030-5
24. Francis J, Rai R, Sebire NJ, et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Mol Hum Reprod 2006;12:435-42
25. Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007;196:167.e1-e5
26. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002;195:211-20 (Pubitemid 34461265)
27. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002;61(Suppl 2): ii46-50
28. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112:1644-54
29. Redecha P, Franzke CW, Ruf W, et al. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 2008;118:3453-61
30. Girardi G, Mackman N. Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule. Lupus 2008;17:931-6
31. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005;106:2340-6
32. Pierangeli SS, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005;52:2120-4 (Pubitemid 40994335)
33. Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteix B, et al. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta2-glycoprotein I antibodies. Thromb Haemost 2002;88:851-7
34. Espinola RG, Liu X, Colden-Stanfield M, et al. E-Selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2003;1:843-8
35. Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2 glycoprotein I antibodies. Int Immunol 2004;16:1633-41
36. Vega-Ostertag M, Casper K, Swerlick R, et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005;52:1545-54
37. Simoncini S, Sapet C, Camoin-Jau L, et al. Role of reactive oxygen species and p38MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. Int Immun 2005;17:489-500
38. Montiel-Manzano G, Romay-Penabad Z, Papalardo de Martinez E, et al. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Ann NY Acad Sci 2007;1108:540-53
39. Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z, et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost 2007;5:1828-34
40. Kubota T, Fukuya Y, Hashimoto R, et al. Possible involvement of chemokine-induced platelet activation in thrombophilic diathesis of antiphospholipid syndrome. Ann NY Acad Sci 2009;1173:137-45
41. Barone FC, Irving EA, Ray AM, et al. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther 2001;296:312-21
42. Branger J, van den Blink B, Weijer S, et al. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 2003;101:4446-8
43. Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res 2004;114:467-76
44. Espinola RG, Pierangeli SS, Ghara AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002;87:518-22
45. Pierangeli SS, Vega-Ostertag ME, Gonzalez EB. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Rev Mol Med 2007;9:1-15
46. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009;68:238-41
47. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009;61:29-36
48. Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002;41:924-9
49. Pierangeli SS, Vega-Ostertag ME, Raschi E, et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007;66:1327-33
50. Ma K, Simantov R, Zhang JC, et al. High affinity binding of beta2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000;275:15541-8
51. Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 2005;105:1964-9
52. Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009;114:3074-83
53. Furberg CD. Natural statins and stroke risk. Circulation 1999;99:185-8
54. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001;44:2870-8
55. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004;2:1558-63
56. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003;48:3272-9
57. Girardi G. Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. J Reprod Immunol 2009;82:126-31
58. Redecha P, van Rooijen N, Torry D, Girardi G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood 2009;113:4101-9
59. Sorice M, Longo A, Capozzi A, et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007;56:2687-97
60. Jajoria P, Murthy V, Papalardo E, et al. Statins for the treatment of antiphospholipid syndrome? Ann NY Acad Sci 2009;1173:736-45
61. Cortellaro M, Cofrancesco E, Arbustini E, et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 2002;88:41-7
62. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-82
63. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1851-61
64. Ioannou Y, Lambrianides A, Cambridge G, et al. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis 2008;67:425-6
65. Erkan D, Lockshin MD. Non-criteria manifestations of antiphospholipid syndrome. Lupus 2010;19:424-7
66. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998;95:15542-6
67. Iverson GM, Reddel S, Victoria EJ, et al. Use of single point mutations in domain I of beta2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002;169(12):7097-103
68. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005;105:1540-5
69. de Laat B, Derksen RH, van Lummel M, et al. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006;107:1916-24
70. Ioannou Y, Pericleous C, Giles I, et al. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta2-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007;56:280-90
71. Ioannou Y, Giles I, Lambrianides A, et al. A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnol 2006;6:8
72. Ioannou Y, Romay-Penabad Z, Pericleous C, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 2009;7:833-42
73. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009;60:1232-41
74. Salmon JE, Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol 2008;77:51-6